Feng-Ming (Spring) Kong, MD, PhD, Master in clinical trial design and data analysis, American Board Certified Radiation Oncologist, Fellow of the American College of Radiology (FACR), Fellow of the American Association of Women Radiologists (FAAWR) and Fellow of American Society for Radiation Oncology (FASTRO), is a clinical professor, Director of Imaging and Blood Biomarker Group, Director of Thoracic Oncology Center and Deputy Cancer Center Director, HKU Shen-Zhen Hospital, Li Ka Shing faculty of Medicine, the University of Hong Kong. Professor Kong is a graduate of Radiation Oncology Residency Program from the Washington University in St. Louis  and also had Radiation Oncology Residency training from Shanghai Cancer Hospital/Fudan University and postdoctoral training at Duke University. As a radiation oncologist in United States, Professor Kong has served as an expert panelist of National Cancer Network (NCCN) Guideline and ACR radiation oncology practice appropriateness guidelines. Dr. Kong received numerous awards including prestigious young investigator award and career developmental award from American Society of Clinical Oncology (ASCO), NIH R21 and R01 as the Principal Investigator and P01 as a Key Investigator from NIH/NCI of the United States. Professor Kong served as the leader of thoracic radiation oncology research program, director of Clinical Research, Chair of Radiation Oncology Department and associate director of Cancer Center, Co-Leader of MultiD Thoracic Oncology Program. She served as the President of American Association for Women Radiologists Radiation Oncologists. During her tenure in Hong Kong China, she has secured funding of 40+ million RMB including China NSF and a platform grant of high-level talents on clinical trial. Upto October 2023, Professor Kong has published 280 scientific publications, with over 10,000 citations, was listed among the top 1% scientists in the field of lung cancer in 2020 and 1% published in radiation pneumonitis in 2021. Professor Kong has served as a reviewer for more than 20 Journals, and served as a member of editorial boards of top oncology journals like Journal of Clinical Oncology (JCO, IF 50s in 2023) and the best Radiation Oncology Journal, the International Journal of Radiation Oncology (Red Journal,IF8.0). She is currently as an associate editor of the Journal of the National Cancer Centre (JNCC), the official Journal of China Health administration commission, Co-Editor-in-Chief for Intelligent Oncology sponsored the Chinese Anti-Cancer Association and editorial roles in other journals like frontier Oncology. She is the founding President of the Sino-American Network of Radiation Oncology (SANTRO), the inaugural Chair of the SANTRO Board Directors. Professor Kong is Chair of the WHO STAR Oncology Guidelines Assessment Commission of the WHO Collaborating Centre, and the President of the Global Cancer Collaborative Group (GCOG).

Below is the list of Prof. Kong's titles :

Leader of A Peacock Project on Innovative Clinical Trial Platform on Radiation and Immunotherapy
Leader of A Peacock Project on RT and Immunotherapy
B-file talents of Health Commission of Shenzhen 
Professor of Clinical Oncology/Deputy Director of Oncology Medical Center/Director of Thoracic Oncology Spelciaty, HKU-SZH, The University of Hong Kong
President of Global Collaborative Oncology Group (GCOG) （2019-present）
Co-chair for ACLC 2024
Deputy Director of Overseas Expert Committee of China CSCO Clinical Oncology Society
STAR Guideline Chair for Oncology
Fellow of American College of Radiology (FACR)
Fellow of American association for Women Radiologists/Radiation Oncologists (FAAWR)
Fellow of American Society of Radiation Oncology（FASTRO）
Advanced Radiation Technology (ART) , Expert leader on RT OAR contouring guideline(2022)
Expert reviewer for ASTRO guideline on lung cancer (2020-present)
Served as expert panelist for NCCN guideline (most commonly worldwide) (2008-2013) 
Served as NIH/NCI R21/P01/R01 funded principal investigator,Received numerous awards such as ASCO YIA and ASCO CDA
260+ publications (10000+ citations), listed in the top 1% scholar for citation in 2020
In 2021, the peer published radiation pneumonia up to 1% of scholars
Director of innovative adaptive radiotherapy RTOG1106 in US
Served as editorial board member of many top Journals including Red Journal, clinical lung cancer, JCO (IF=50) 
National PI of RTOG1106 on adaptive RT, translational research co-chair for RTOG SBRT trials RTOG618 and RTOG813.
Served as Chair of Radiation Oncology department and Associate Cancer Center Director at Medical College of Georgia (2013-2016)
Served as a co-leader of Thoracic Oncology Program at Indiana University School of Medicine and Cancer Center of Georgia (2016-2018)
President of AAWR  （2015） President of AAWR Research and Foundation (2016)
Founding President of SANTRO (2008-2010) and Chair of SANTRO Board Directors (2006-2012)

1. Huang YH, Ren G, Xiao H, Yang D, Kong FS, Ho WY, Cai J. Volumetric multiphase ventilation imaging based on four-dimensional computed tomography for functional lung

   avoidance radiotherapy. Med Phys. 2022 Nov;49(11):7237-7246. doi: 10.1002/mp.15847. Epub 2022 Jul 22. PMID: 35841346. IF: 4.506/Q2, RADIOLOGY, NUCLEAR MEDICINE &

   MEDICAL IMAGING-SCIE(Q2), Citations:0

2. Li L, Zheng J, Liu Z, Huang Y, Xiao J, Wang S, Yu Q, Zhang Q, Hu X, Zhao W, Hou W, Spring Kong FM, Yu J, Yuan S. Pre-treatment 18F-RGD Uptake may Predict Adverse Events during Apatinib Antiangiogenic Therapy. Clin Oncol (R Coll Radiol). 2022 Jun;34(6):e238-e245. doi: 10.1016/j.clon.2022.01.002. Epub 2022 Jan 19. PMID: 35063328.
3. Zhang J, Teng X, Lam S, Sun J, Cheung AL, Ng SC, Lee FK, Au KH, Yip CW, Lee VH, Lin Z, Liang Y, Yang R, Han Y, Zhang Y, Kong FS, Cai J. Quantitative Spatial Characterization of

   Lymph Node Tumor for N Stage Improvement of Nasopharyngeal Carcinoma Patients. Cancers (Basel). 2022 Dec 30;15(1):230. doi: 10.3390/cancers15010230. PMID: 36612236; PMCID: PMC9818273. IF: 6.575/Q1, ONCOLOGY-SCIE(Q1), Citations:0

4. Milano MT, Doucette C, Mavroidis P, Yorke E, Ryckman J, Mahadevan A, Kapitanova I, Kong FS, Grimm J, Marks LB. Hypofractionated Stereotactic Radiation Therapy Dosimetric Tolerances for the Inferior Aspect of the Brachial Plexus: A Systematic Review. Int J Radiat Oncol Biol Phys. 2023 Jan 20:S0360-3016(22)03525-8. doi: 10.1016/j.ijrobp.2022.11.012. Epub ahead of print. PMID: 36682981. IF: 8.013/Q1, ONCOLOGY-SCIE(Q1), RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-SCIE(Q1), Citations:0 
5. Yang D, Ren G, Ni R, Huang YH, Lam NFD, Sun H, Wan SBN, Wong MFE, Chan KK, Tsang HCH, Xu L, Wu TC, Kong FS, Wáng YXJ, Qin J, Chan LWC, Ying M, Cai J. Deep learning attention-guided radiomics for COVID-19 chest radiograph classification. Quant Imaging Med Surg. 2023 Feb 1;13(2):572-584. doi: 10.21037/qims-22-531. Epub 2022 Nov 21. PMID: 36819269; PMCID: PMC9929417. IF: 4.63/Q2, RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-SCIE(Q2)
6. Milano MT, Mavroidis P, Ryckman J, Yorke E, Doucette C, Mahadevan A, Kapitanova I, Spring Kong FM, Marks LB, Grimm J. Radiation-Induced Inferior Brachial Plexopathy after

   Stereotactic Body Radiotherapy: Pooled Analyses of Risks. Radiother Oncol. 2023 Feb 24:109583. doi: 10.1016/j.radonc.2023.109583. Epub ahead of print. PMID: 36842665.

7. Lam TC, Cho WC, Au JS, Ma ES, Lam ST, Loong HH, Wong JWH, Wong SNM, Lee VH, Leung RC, Lau JK, Kam MT, Mok FS, Lim FM, Nyaw JS, Tin WW, Cheung KM, Chan OS,

   Kwong PW, Cheung FY, Poon DMC, Chik JY, Lam MH, Chan LW, Wong SC, Cao YB, Hui CV, Chen JZ, Chang JH, Kong SF, El Helali A; Precision Oncology Working Group (POWG).

   Consensus Statements on Precision Oncology in the China Greater Bay Area. JCO Precis Oncol. 2023 Jun;7:e2200649. doi: 10.1200/PO.22.00649. PMID: 37315266; PMCID: PMC10309548.

8. Zhou L, Liu Y, Wu Y, Yang X, Spring Kong FM, Lu Y, Xue J. Low-dose radiation therapymobilizes antitumor immunity: New findings and future perspectives. Int J Cancer. 2024 Apr

   1;154(7):1143-1157. doi: 10.1002/ijc.34801. Epub 2023 Dec 7. PMID: 38059788.

9. Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM,

   Chan AC. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced,

   unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):169-178. doi: 10.1016/S2468-1253(22)00339-9. Epub

   2022 Dec 15. PMID: 36529152.

10. Chiang CL, Lam TC, Li JCB, Chan KSK, El Helali A, Lee YYP, Law LHT, Zheng D, Lo AWI, Kam NW, Li WS, Cheung AKW, Chow JCH, Chan SPC, Lai JWY, Lee SWM, Kong FS, Ng

    WT, Kwong DLW, Lee AWM. Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial. Lancet Reg Health West Pac. 2023 Sep 6;40:100898. doi: 10.1016/j.lanwpc.2023.100898. PMID: 37701718; PMCID: PMC10493598.

11. Lan Y, Pi W, Zhou Z, Meng Y, DanMei, Xu Y, Xia X, WeiWang, Yang H, Spring Kong FM. Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung

    cancer. Int Immunopharmacol. 2023 Nov;124(Pt B):110956. doi: 10.1016/j.intimp.2023.110956. Epub 2023 Sep 24. PMID: 37751656.

12. Meng Y, Sun H, Wang S, Yang H, Kong FS. Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):415-426. doi: 10.1016/j.ijrobp.2023.09.009. Epub 2023 Sep 14. PMID: 37716460.
13. Ruan J, Zhao Z, Qian Y, Xu R, Liao G, Kong FS. The predictive role of soluble programmed death ligand 1 in digestive system cancers. Front Oncol. 2023 Jul 13;13:1170220. doi:

    10.3389/fonc.2023.1170220. PMID: 37519785; PMCID: PMC10374258.

14. Zhang J, Yang L, Li H, Chan JW, Lee EKW, Liu M, Ma L, Liu Q, Jin JY, Fu P, Xu Z, Kong FS. Dosimetric Effect of Thymus and Thoracic Duct on Radiation-Induced Lymphopenia in Patients With Primary Lung Cancer Who Received Thoracic Radiation. Adv Radiat Oncol. 2023 May 1;8(6):101260. doi: 10.1016/j.adro.2023.101260. PMID: 38047216; PMCID: PMC10692302.
15. Milano MT, Mavroidis P, Yorke E, Ryckman J, Kong FS, Grimm J, Marks LB. In Reply to Onjukka et al. Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):1145-1146. doi: 10.1016/j.ijrobp.2023.08.067. Epub 2024 Feb 22. PMID: 38401970.  Milano MT, Mavroidis P, Ryckman J, Yorke E, Doucette C, Mahadevan A, Kapitanova I, Spring Kong FM, Marks LB, Grimm J. Radiation-induced inferior brachial plexopathy after stereotactic body radiotherapy: Pooled analyses of risks. Radiother Oncol. 2023 May;182:109583. doi: 10.1016/j.radonc.2023.109583. Epub 2023 Feb 25. PMID: 36842665; PMCID: PMC10501316.                                                  
16. Huang YH, Teng X, Zhang J, Chen Z, Ma Z, Ren G, Kong FS, Ge H, Cai J. Respiratory Invariant Textures From Static Computed Tomography Scans for Explainable Lung Function Characterization. J Thorac Imaging. 2023 Sep 1;38(5):286-296. doi: 10.1097/RTI.0000000000000717. Epub 2023 May 29. PMID: 37265243.   
17. Sui H, Xiao S, Jiang S, Wu S, Lin H, Cheng L, Ye L, Zhao Q, Yu Y, Tao L, Kong FM, Huang X, Cui R. Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells. Neoplasia. 2023 May;39:100897. doi: 10.1016/j.neo.2023.100897. Epub 2023 Mar 20. PMID: 36940556; PMCID: PMC10036942.                                                                                                                                                                        
18. Niu GM, Gao MM, Wang XF, Dong Y, Zhang YF, Wang HH, Guan Y, Cheng ZY, Zhao SZ, Song YC, Tao Z, Zhao LJ, Meng MB, Spring Kong FM, Yuan ZY. Dosimetric analysis of

    brachial plexopathy after stereotactic body radiotherapy: Significance of organ delineation.Radiother Oncol. 2024 Jan;190:110023. doi: 10.1016/j.radonc.2023.110023. Epub 2023 Nov 22.PMID: 37995850.

19. Yiu WS, Chu TSM, Meng Y, Kong FS. DNA Repair Genetics and the Risk of Radiation Pneumonitis in Patients With Lung Cancer: A Systematic Review and Meta-analysis. Clin Oncol (R Coll Radiol). 2024 Mar 24:S0936-6555(24)00117-1. doi: 10.1016/j.clon.2024.03.019. Epub ahead of print. PMID: 38653664.
20. May Abdel-Wahab, C Norman Coleman, Jesper Grau Eriksen, Peter Lee, Ryan Kraus, Ekaterina Harsdorf, Becky Lee, Adam Dicker, Ezra Hahn, Jai Prakash Agarwal, Pataje G S Prasanna, Michael MacManus, Paul Keall, Nina A Mayr, Barbara Alicja Jereczek-Fossa, Francesco Giammarile, In Ah Kim, Ajay Aggarwal, Grant Lewison, Jiade J Lu, Douglas Guedes de Castro, Feng-Ming (Spring) Kong, Haidy Affff, Hamish Sharp, Verna Vanderpuye, Tajudeen Olasinde, Fadi Atrash, Luc Goethals, Benjamin W Corn, Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities, Lancet Oncol 2024, 03-Apr-24